Rabies immunoglobulin


Concise Prescribing Info
Indications/Uses
Postexposure prophylaxis of rabies.
Dosage/Direction for Use
Adult : Inj/IM In conjunction with rabies vaccine in unvaccinated individuals: As HRIG: 20 IU/kg. As ERIG: 40 IU/kg. Dose is given with the 1st dose of rabies vaccine (or within 7 days after), to be administered by infiltration in or around the cleansed wound; any remainder may be injected via IM inj.
Dosage Details
Parenteral
Postexposure prophylaxis of rabies
Adult: In conjunction with rabies vaccine in unvaccinated individuals: As human rabies immunoglobulin (HRIG): 20 IU/kg. As equine rabies immunoglobulin (ERIG): 40 IU/kg. Administer as a single dose on the 1st day of rabies vaccine (or within 7 days after) via infiltration into and around the cleansed wound. If infiltration of the whole volume is not possible, any remaining dose may be injected intramuscularly in the deltoid muscle of the upper arm or anterolateral thigh (distant from the site of rabies vaccine administration).
Child: Same as adult dose.
Contraindications
Hypersensitivity.
Special Precautions
Patients with IgA deficiency, bleeding disorders (e.g. thrombocytopenia) or those who are at risk of thrombosis (e.g. prolonged immobilisation, history of thrombosis, hyperviscosity syndrome). Children. Pregnancy and lactation.
Adverse Reactions
Significant: Haemolysis, bleeding, haematoma, fever; injection site reactions (e.g. swelling, pain, erythema, warmth).
Cardiac disorders: Tachycardia.
Gastrointestinal disorders: Nausea and vomiting.
General disorders and administration site conditions: Fatigue, malaise, influenza like illness.
Musculoskeletal and connective tissue disorders: Chills, arthralgia.
Nervous system disorders: Headache.
Skin and subcutaneous tissue disorders: Pruritus, rash, urticaria.
Potentially Fatal: Rarely, severe hypersensitivity reactions (e.g. anaphylactic shock).
IM/Parenteral: C
MonitoringParameters
Perform skin testing prior to administration of ERIG.
Drug Interactions
May interfere with immune response to live attenuated virus vaccines. Immunosuppresive agents (e.g. alkylating agents, metabolites, corticosteroids, radiation) may increase risk of rabies infection due to decrease in antibody response to postexposure prophylaxis. Increased risk of bleeding with anticoagulants.
Lab Interference
May cause false-positive results in serological tests.
Action
Description: Rabies immunoglobulin (RIG) is used for passive immunisation for individuals who are exposed to rabies virus and who have not been vaccinated against rabies. It provides immediate, temporary virus-neutralising antibodies until response to active immunisation with rabies vaccine is achieved. There are 2 kinds of rabies immunoglobulin based on their sources: human rabies immunoglobulin (HRIG) and highly purified equine rabies immunoglobulin (ERIG).
Pharmacokinetics:
Absorption: Absorbed slowly after IM administration.
Excretion: Serum half-life: Approx 21 days (IM).
Storage
Store between 2-8°C. Do not freeze. Protect from light.
ATC Classification
J06BB05 - rabies immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.
Disclaimer: This information is independently developed by MIMS based on Rabies immunoglobulin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in